Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)

Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.

Original reporting
Published Aug 28, 2026, 12:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 7:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) — source image
Decision brief

The 30-second read

$NEOBullishLow
01

Why it matters

Price target revisions provide modest upside cues but lack rating changes, limiting immediate trading urgency.

02

Market read

Analyst target updates may influence niche biotech investors but are unlikely to drive broad market moves.

03

What to watch

Potential regulatory or clinical trial setbacks not addressed.

Relevance 4/10Novelty 3/10Timing: today

Background

Analyst coverage updates for three small‑cap biotech firms.

Company-level read

Ticker impact

$NEOBullishMedium confidence
Context

Piper Sandler analyst maintained a Buy rating on NeoGenomics and set a new price target of $21.00.

Expected impact

Potential modest price appreciation if market follows target.

Evidence & confidence

Target implies ~21% upside from current price; no rating change reduces urgency.

$LONABullishMedium confidence
Context

Piper Sandler analyst maintained a Buy rating on LeonaBio with a price target of $20.00.

Expected impact

Possible price rise toward target if investors act on the target.

Evidence & confidence

Target suggests ~156% upside; however, rating unchanged limits immediate impact.

$SLDBBullishMedium confidence
Context

Cantor Fitzgerald analyst maintained a Buy rating on Solid Biosciences and set a price target of $26.00.

Expected impact

Potential upside if market aligns with target expectations.

Evidence & confidence

Target reflects ~168% upside; lack of rating change suggests limited short‑term catalyst.

Market effects

Reinforces bullish sentiment in niche biotech sector.

Limited to U.S. biotech investors.

Minimal global impact beyond sector.

Counterpoint

Analyst targets may be overly optimistic given recent sector volatility.

Key entities

  • NeoGenomics

    US‑listed biotech firm.

  • LeonaBio

    US‑listed biotech firm.

  • Solid Biosciences

    US‑listed biotech firm.

Related articles

$SLDBMed

Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported Q3 2026 results, highlighting progress in its Duchenne and Friedreich’s ataxia programs. SGT-003 was well tolerated in 53 participants, with an FDA meeting scheduled for Q4 2026 to discuss accelerated approval. SGT-212 dosed five participants in its Phase 1b trial. The company had $348.9M in cash as of Q3 2026, expecting funding into 2028. Q3 net loss was $53.9M, up from $45.8M in Q3 2025.

$NEOMed

NeoGenomics Inc (NEO) Q3 2026 Earnings Call Highlights: Revenue Tops $209 Million as NGS

NeoGenomics Inc (NEO) reported Q3 2026 revenue of $209M, driven by 11% AUP growth from NGS products and RCM initiatives. CEO Tony Zook announced a transition to Warren Stone, emphasizing strategic alignment. The company expects continued AUP growth and slight pharma segment recovery in 2027, despite potential Medicare rate cuts. NGS volume growth is attributed to new products and sales force expansion.